Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 6:07 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 3,710 matching trials from the live ClinicalTrials.gov search.
Conditions
Type 2 Diabetes Mellitus
Interventions
Alogliptin, Metformin, Glipizide
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
2,639 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
94
States / cities
Montgomery, Alabama • Muscle Shoals, Alabama • Pell City, Alabama + 91 more
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin aspart, insulin detemir
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
33
States / cities
Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 28 more
Conditions
Diabetic Ketoacidosis, Type 1 Diabetes, Type 2 Diabetes
Interventions
Early Glargine, Late Glargine, IV insulin infusion, IV fluid and electrolytes replacement
Drug · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Completed Not applicable Interventional Results available

Time in Glucose Hospital Target

NCT05135676
Conditions
Diabetes Mellitus, Type 2
Interventions
Blinded CGM, real-time CGM
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
Aurora, Colorado • Atlanta, Georgia • Baltimore, Maryland + 3 more
Conditions
Type 2 Diabetes
Interventions
Literacy/Numeracy oriented educational intervention, Control Group
Behavioral
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 85 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Type 1 Diabetes Mellitus, Glucokinase-Maturity Onset Diabetes of the Young (GCK-MODY), MODY2 Diabetes, Healthy Volunteer
Interventions
Study Visit 1, Placebo, Study Visit 2, Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor
Procedure · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 60 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Recruiting Not applicable Interventional

Diabetes Body Project 2

NCT07468188
Conditions
Eating Disorders, Type 2 Diabetes
Interventions
Body Project Type 2
Behavioral
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Type 2 Diabetes
Interventions
Text messaging, Virtual workshop
Behavioral
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
13 Years to 19 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
New York, New York
Recruiting Not applicable Interventional

PILI 'Āina Household

NCT06526273
Conditions
Type 2 Diabetes, Hypertension, Dyslipidemias, Overweight and Obesity
Interventions
PILI 'Āina, Control
Behavioral · Other
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
2
States / cities
Honolulu, Hawaii • Kapolei, Hawaii
Conditions
Diabetes Mellitus, Type 2, Glucose, High Blood, Glucose Metabolism Disorders
Interventions
Diazoxide, Placebo (for diazoxide), Nicotinic acid
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
21 Years to 70 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
The Bronx, New York
Conditions
Type 2 Diabetes Mellitus (T2D)
Interventions
Food Bundle Intervention
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Completed Phase 2 Interventional Accepts healthy volunteers

Mood and Insulin Resistance in Adolescents At-Risk for Diabetes

NCT01425905
Conditions
Depression, Impaired Glucose Tolerance
Interventions
The Blues Program, Hey Durham
Other
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
12 Years to 17 Years · Female only
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Active, not recruiting Not applicable Interventional

Eversense® Non-adjunctive Use Post Approval Study

NCT04836546
Conditions
Diabetes
Interventions
Blood glucose meter, Eversense CGM System
Device
Lead sponsor
Senseonics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
925 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
23
States / cities
Los Angeles, California • Englewood, Colorado • Hamden, Connecticut + 20 more
Enrolling by invitation Early Phase 1 Interventional

Truway Diagnostic Tools in Primary Care

NCT07209527
Conditions
Chronic Disease, Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight, Hypertension, Cardiovascular Disease Acute, Hyperlipidemia, Chronic Kidney Disease (CKD), Stages 3-4 Exercise Tolerance / Functional Capacity Vascular Health / Arterial Stiffness Fatigue in CKD, Peripheral Artery Disease, Metabolic Syndrome, Prediabetes
Interventions
Truway Portable Ultrasound Device, Truway Blood Glucose Monitor, Standard Oral Hypoglycemic Agent
Device · Drug
Lead sponsor
Truway Health, Inc.
Industry
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Conditions
Chronic Kidney Diseases, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Diabetes Mellitus, Diabetic Nephropathies
Interventions
Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion, Allogeneic adipose-derived mesenchymal stem cells (MSC)-Two Infusions
Drug
Lead sponsor
LaTonya J. Hickson
Other
Eligibility
30 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Conditions
Type 2 Diabetes Mellitus
Interventions
Bexagliflozin, Placebo
Drug
Lead sponsor
Theracos
Industry
Eligibility
20 Years and older
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
23
States / cities
Fresno, California • La Palma, California • Lincoln, California + 19 more
Completed Not applicable Interventional

Examining The Role of CGM in T2DM

NCT01614262
Conditions
DIABETES MELLITUS, NONINSULIN-DEPENDENT, 2 (Disorder)
Interventions
Continuous Glucose Monitoring with treatment algorithm
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
2
States / cities
Atlanta, Georgia • Chapel Hill, North Carolina
Conditions
Diabetes Mellitus, Type 2
Interventions
Use of a PDA to assist shared decision making
Behavioral
Lead sponsor
EPI-Q
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
2
States / cities
Oak Brook, Illinois
Conditions
Diabetes Mellitus, Type 2
Interventions
rosiglitazone, placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Overweight or Obese, Type 2 Diabetes Mellitus (T2DM)
Interventions
Placebo, Enicepatide
Drug
Lead sponsor
Carmot Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
447 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
52
States / cities
Birmingham, Alabama • Guntersville, Alabama • Yuma, Arizona + 45 more
Conditions
Diabetes Mellitus, Type 2
Interventions
Neutral Protamine Hagedorn (NPH), Detemir insulin
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Female only
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Houston, Texas
Conditions
Diabetes Mellitus
Interventions
JTT-251 or Placebo
Drug
Lead sponsor
Shionogi Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Orlando, Florida
Conditions
Type 2 Diabetes Mellitus
Interventions
Ginkgo biloba extract
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
20 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
San Antonio, Texas
Completed Phase 3 Interventional Results available

Add-on to Thiazolidinedione (TZD) Failures

NCT00683878
Conditions
Type 2 Diabetes
Interventions
Dapagliflozin, Placebo matching Dapagliflozin, Thiazolidinedione (Pioglitazone)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
972 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
57
States / cities
Anniston, Alabama • Ozark, Alabama • Phoenix, Arizona + 51 more